Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02014337
Title Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Corcept Therapeutics

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

peritoneum cancer

urethra transitional cell carcinoma

breast cancer

fallopian tube cancer


prostate cancer

ovarian cancer

lung non-small cell carcinoma

triple-receptor negative breast cancer


Eribulin + Mifepristone

Age Groups:
Covered Countries USA

No variant requirements are available.